Universitaetsklinikum Tuebingen AöR
Tuebingen, Germany
Not recruiting
Study on Amantadine Hemisulfate for Patients with Unresponsive Wakefulness Syndrome in Intensive and Intermediate Care Units
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying a condition known as unresponsive wakefulness syndrome, which is a state where a person is awake but not showing signs of awareness. The treatment being tested in this study is a medication called Amantadine, specifically in the form of Amantadin-ratiopharm® 200 mg Infusion Solution. This medication is administered through an infusion, which means it is delivered directly into the bloodstream over a period of time.
The purpose of the study is to see if Amantadine can help improve the alertness and responsiveness of patients who are in intensive or intermediate care units. The study will last for a total of five days, during which the patients will receive the medication. The main goal is to observe any changes in the patients' level of alertness, which will be measured using a tool called the Glasgow Coma Scale (GCS). This scale helps doctors assess a person's level of consciousness.
Throughout the study, the patients' progress will be monitored using various scales and checklists, such as the Richmond Agitation-Sedation Scale (RASS) and the Coma Recovery Scale Revised (CRSR). These tools help provide a comprehensive view of the patients' condition and any improvements in their responsiveness. The study aims to gather valuable information on the effectiveness of Amantadine in enhancing the recovery of patients with reduced consciousness.
The research process
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
6 criteria
- The patient or their legal representative must understand the study procedures and sign a document agreeing to participate.
- If the patient is a woman who can have children, a test must show she is not pregnant before starting the study medication.
- The patient must have reduced consciousness for at least 72 hours, which means they have a **Glasgow Coma Scale (GCS)** score of less than 8. The GCS is a way to measure how awake and responsive a person is.
- The patient's **EEG** (a test that checks brain activity) and **ECG** (a test that checks heart activity) must not show any unusual results.
- Both male and female patients can participate.
- The study includes patients who are considered a vulnerable population, meaning they might need extra protection or care.
Who cannot join the trial?
10 criteria
- Patients who have allergies or bad reactions to the study medication, Amantadine, cannot participate.
- Individuals with severe kidney problems, as the medication may not be safe for them.
- Patients with a history of seizures, which are sudden, uncontrolled electrical disturbances in the brain, are excluded.
- People with severe liver disease, as the medication could affect their liver function.
- Pregnant or breastfeeding women, to avoid any potential risk to the baby.
- Individuals who are currently participating in another clinical trial, to prevent interference with study results.
- Patients who have a history of drug or alcohol abuse, which could affect the study outcomes.
- Anyone with a mental health condition that might interfere with their ability to follow study instructions.
- Patients who have had a recent major surgery, as recovery could affect the study results.
- Individuals with certain heart conditions, as the medication might not be safe for them.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Verified
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Amantadine is being studied for its potential to improve alertness and responsiveness in patients who are in intensive and intermediate care units. The trial aims to see if this medication can effectively increase the level of consciousness, as measured by clinical scores like the Glasgow Coma Scale, after five days of treatment.
What is already known about the treatment
Amantadine – Amantadine is administered orally in the form of capsules or tablets. It is currently being studied in clinical trials for its potential to enhance alertness and responsiveness in patients with unresponsive wakefulness syndrome. The main therapeutic indication being explored is its ability to improve vigilance and responsiveness, as measured by clinical scores like the Glasgow Coma Scale. At the molecular level, Amantadine works by influencing neurotransmitter activity in the brain, particularly affecting dopamine release and reuptake. It is classified pharmacologically as an antiviral and antiparkinsonian agent.
Investigated diseases
Unresponsive Wakefulness Syndrome – This condition, also known as a vegetative state, occurs when a person is awake but not aware of themselves or their environment. It often follows severe brain injury, where the patient may open their eyes, have sleep-wake cycles, and exhibit basic reflexes, but lacks conscious awareness. Over time, some individuals may show minimal signs of awareness, but many remain in this state for extended periods. The condition is characterized by the absence of voluntary actions or purposeful responses to stimuli. It is distinct from a coma, as patients in unresponsive wakefulness syndrome have periods of wakefulness. The progression of this condition varies, with some patients showing slight improvements, while others may remain unchanged.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-512333-33-00Protocol code2021-10Estimated enrolment50 patientsSponsorUniversitaetsklinikum Tuebingen AöR
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?